▲ +29.69% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Arcus Biosciences in the last 3 months. The average price target is $47.64, with a high forecast of $70.00 and a low forecast of $34.00. The average price target represents a 29.69% upside from the last price of $36.73.
The current consensus among 9 contributing investment analysts is to buy stock in Arcus Biosciences. This Buy consensus rating has held steady for over two years.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer therapies in the United States. The company's product pipeline includes, AB928, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 monoclonal antibody that is in Phase Ib clinical trial for monotherapy. It is also developing AB154, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab and AB928; and AB680, small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer. Arcus Biosciences, Inc. has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca to evaluate domvanalimab (AB154), its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; license agreements with Taiho Pharmaceutical Co., Ltd and Abmuno Therapeutics LLC; and strategic relationship with WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was founded in 2015 and is based in Hayward, California.